Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › MariTide

MariTide

GLP-1 + GIPR antagonist (antibody) · s.c. monthly · Amgen

Data cut 12 November 2026 · page built 16 November 2026 · 9 trial arms · 3 trials with results · 12 registered trials · see on the pipeline board

Summary

Also known as
maridebart cafraglutide
Mechanism
GLP-1 + GIPR antagonist (antibody)
Route
s.c. monthly
Company
Amgen
Highest development stage
phase 3
Status (as of data cut)
Phase 3 (MARITIME) verify
Next milestone
MARITIME-1/-2 readouts 2027

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingMARITIME phase 3 programme ongoing
T2D2 phase 3 ongoingPhase 3 ongoing
CV outcomes2 phase 3 ongoingPhase 3 ongoing
CKD0 no data
HFpEF2 phase 3 ongoingPhase 3 ongoing
MASH0 no data
Sleep apnoea2 phase 3 ongoingPhase 3 ongoing
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
MariTide phase 2 (obesity cohort)MariTide 140 mg every 4 weeks (no escalation)obesity5277−16.3 % vs −2.6 %
Δ −13.7 pp
−13.6 % vs −2.5 %
Δ −11.1 pp
—14.0 vs 1.0—77.0 vs 25.068.0 vs 3.05.0 vs 7.0—verified
MariTide phase 2 (obesity cohort)MariTide 280 mg every 4 weeks (no escalation)obesity5277−19.9 % vs −2.6 %
Δ −17.3 pp
−15.5 % vs −2.5 %
Δ −13.0 pp
—14.0 vs 1.0—78.0 vs 25.073.0 vs 3.05.0 vs 7.0—verified
MariTide phase 2 (obesity cohort)MariTide 420 mg every 4 weeks (no escalation)obesity5279−18.9 % vs −2.6 %
Δ −16.3 pp
−14.6 % vs −2.5 %
Δ −12.1 pp
—22.0 vs 1.0—87.0 vs 25.087.0 vs 3.06.0 vs 7.0—verified
MariTide phase 2 (obesity cohort)MariTide 420 mg every 8 weeks (no escalation)obesity5251−17.7 % vs −2.6 %
Δ −15.1 pp
−12.3 % vs −2.5 %
Δ −9.8 pp
—29.0 vs 1.0—82.0 vs 25.092.0 vs 3.014.0 vs 7.0—verified
MariTide phase 2 (obesity cohort)MariTide 420 mg every 4 weeks, 4-week dose escalationobesity5251−16.7 % vs −2.6 %
Δ −14.1 pp
−14.1 % vs −2.5 %
Δ −11.6 pp
—10.0 vs 1.0—71.0 vs 25.043.0 vs 3.00.0 vs 7.0—verified
MariTide phase 2 (obesity cohort)MariTide 420 mg every 4 weeks, 12-week dose escalationobesity5252−19.9 % vs −2.6 %
Δ −17.3 pp
−16.2 % vs −2.5 %
Δ −13.7 pp
—12.0 vs 1.0—73.0 vs 25.044.0 vs 3.06.0 vs 7.0—verified
MariTide phase 2 (obesity with T2D cohort)MariTide 140 mg every 4 weeks (no escalation)t2d5231−12.3 % vs −1.4 %
Δ −10.9 pp
−10.3 % vs −1.7 %
Δ −8.6 pp
−1.6 vs +0.113.0 vs 3.0—58.0 vs 9.045.0 vs 6.03.0 vs 0.0—verified
MariTide phase 2 (obesity with T2D cohort)MariTide 280 mg every 4 weeks (no escalation)t2d5232−12.1 % vs −1.4 %
Δ −10.7 pp
−8.4 % vs −1.7 %
Δ −6.7 pp
−1.2 vs +0.119.0 vs 3.0—41.0 vs 9.050.0 vs 6.06.0 vs 0.0—verified
MariTide phase 2 (obesity with T2D cohort)MariTide 420 mg every 4 weeks (no escalation)t2d5232−17.0 % vs −1.4 %
Δ −15.6 pp
−12.3 % vs −1.7 %
Δ −10.6 pp
−1.5 vs +0.116.0 vs 3.0—59.0 vs 9.075.0 vs 6.012.0 vs 0.0—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (57)
  • MariTide 140 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 140 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 1 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 140 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 140 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 1
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 140 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 140 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 280 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 280 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 2 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 280 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 280 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 2
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 280 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 280 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 420 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 420 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 3 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 420 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 420 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 3
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 420 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 420 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 420 mg every 8 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 420 mg every 8 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 4 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 420 mg every 8 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 420 mg every 8 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 4
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 420 mg every 8 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 420 mg every 8 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 420 mg every 4 weeks, 4-week dose escalation · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 420 mg every 4 weeks, 4-week dose escalation · weight_eff · Table 2, Efficacy estimand, Primary end point; column 5 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 420 mg every 4 weeks, 4-week dose escalation · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 420 mg every 4 weeks, 4-week dose escalation · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 5
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 420 mg every 4 weeks, 4-week dose escalation · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 420 mg every 4 weeks, 4-week dose escalation · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 420 mg every 4 weeks, 12-week dose escalation · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 420 mg every 4 weeks, 12-week dose escalation · weight_eff · Table 2, Efficacy estimand, Primary end point; column 6 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 420 mg every 4 weeks, 12-week dose escalation · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 420 mg every 4 weeks, 12-week dose escalation · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 6
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 420 mg every 4 weeks, 12-week dose escalation · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 420 mg every 4 weeks, 12-week dose escalation · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 140 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 140 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 8 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 140 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 140 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 8
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 140 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 140 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 140 mg every 4 weeks (no escalation) · hba1c · Table 2, Treatment policy estimand, Key secondary; column 8
    Change in glycated hemo- globin — percentage points −0.3 (−0.4 to −0.3) −0.4 (−0.5 to −0.3) −0.3 (−0.3 to −0.2) −0.3 (−0.4 to −0.2) −0.3 (−0.4 to −0.3) −0.3 (−0.4 to −0.3) 0.0 (−0.1 to 0.1) −1.6 (−1.9 to −1.2) −1.2 (−1.7
  • MariTide 280 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 280 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 9 of 1
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 280 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 280 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 9
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 280 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 280 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 280 mg every 4 weeks (no escalation) · hba1c · Table 2, Treatment policy estimand, Key secondary; column 9
    Change in glycated hemo- globin — percentage points −0.3 (−0.4 to −0.3) −0.4 (−0.5 to −0.3) −0.3 (−0.3 to −0.2) −0.3 (−0.4 to −0.2) −0.3 (−0.4 to −0.3) −0.3 (−0.4 to −0.3) 0.0 (−0.1 to 0.1) −1.6 (−1.9 to −1.2) −1.2 (−1.7
  • MariTide 420 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
    Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
  • MariTide 420 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 10 of
    Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
  • MariTide 420 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
    Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
  • MariTide 420 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 10
    Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
  • MariTide 420 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
    Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
  • MariTide 420 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
    Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
  • MariTide 420 mg every 4 weeks (no escalation) · hba1c · Table 2, Treatment policy estimand, Key secondary; column 10
    Change in glycated hemo- globin — percentage points −0.3 (−0.4 to −0.3) −0.4 (−0.5 to −0.3) −0.3 (−0.3 to −0.2) −0.3 (−0.4 to −0.2) −0.3 (−0.4 to −0.3) −0.3 (−0.4 to −0.3) 0.0 (−0.1 to 0.1) −1.6 (−1.9 to −1.2) −1.2 (−1.7

Outcome trials

Ongoing outcome trials

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
MARITIME-CVMariTideObesity with established CVD
Obesity + established CVD, with or without T2D
MACE12800recruiting2028-06-30NCT07037433

Registered trials (12)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
MARITIME-T2D-3
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
T2DPhase 3recruiting2026-10 → 2028-091300recruitingNCT07866066
MARITIME-PEN
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
ObesityPhase 3recruiting2026-10 → 2027-06230recruitingNCT07871409
MARITIME-2-EXTENSION
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
T2DPhase 3recruiting2026-07 → 2027-12950recruitingNCT07684144
MARITIME-1-EXTENSION
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
ObesityPhase 3recruiting2026-07 → 2027-123200recruitingNCT07684235
MARITIME-SWITCH
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
ObesityPhase 3recruiting2026-05 → 2028-01300recruitingNCT07575399
MARITIME-OSA-1
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Sleep apnoeaPhase 3active not recruiting2025-12 → 2027-08250active not recruitingNCT07225686
MARITIME-OSA-2
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
Sleep apnoeaPhase 3active not recruiting2025-11 → 2027-08250active not recruitingNCT07226765
MARITIME-CV
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
CV outcomesPhase 3active not recruiting2025-07 → 2028-0612800NCT07037433
MARITIME-3-J
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
ObesityPhase 3active not recruiting2025-06 → 2027-04279active not recruitingNCT06987695
MARITIME-HF
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
HFpEFPhase 3recruiting2025-06 → 2028-065056recruitingNCT07037459
MARITIME-1
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
ObesityPhase 3active not recruiting2025-03 → 2027-013853active not recruitingNCT06858839
MARITIME-2
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
ObesityPhase 3active not recruiting2025-03 → 2027-011105active not recruitingNCT06858878

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: MariTide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/maritide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.